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Abstract 
Introduction: Cancer-related cognitive impairment (CRCI) or chemo-brain refers to impairment 
across domains of executive functioning amongst cancer patients. Cognitive impairment has 
been reported in patients before, during, and after treatment and is associated with a reduction in 
quality of life. The current study using a prospective longitudinal study design. examines the 
cognitive effects of a novel immunotherapy in chronic lymphocytic leukemia (CLL) patients, an 
under-represented cancer group in CRCI literature. 
Method: Forty-four (44) patients with CLL were assessed at pre-treatment, and upon 6 months, 
and 12 months of receiving treatment in a phase II trial of obinutuzumab, venetoclax, and 
ibrutinib immunotherapy. Cognition was assessed through recommended subjective, self-report 
and objective, neuropsychological assessments: Patient-Reported Outcomes Measurement 
Information System: Cognitive Function (PROMIS-CF), NIH Auditory Verbal Learning Test 
(AVLT), and Controlled Oral Word Association Test (COWAT). Independent-samples t-tests 
and linear mixed models examined effects of prior treatment history, time, and potential 
moderating covariates (e.g. age, and symptoms of depression and anxiety). 
Results: Cognitive impairment was self-reported in 75%-60% of patients across treatment on the 
PROMIS-CF. Cognitive impairment on neuropsychological tests (AVLT and COWAT) was 
observed in 9%-3.6% of patients across treatment. There was no increase in cognitive 
impairment across all measures regardless of prior treatment history or time. Only symptoms of 
depression and anxiety were associated with PROMIS-CF scores across treatment, F (1,67) = 
51.51, p = .00; F (1, 52) = 17.21, p = .00.  
Conclusion: CLL patients show similar rates of CRCI as other cancer groups. These findings 
suggest CLL patients are not at increased risk for cognitive impairment at pre-treatment 
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assessment and across time. Further research is necessary to validate the findings of this novel 
study.  
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Introduction 
Cancer and cancer treatment have been associated with cognitive impairment in patients. 
This impairment, termed cancer-related cognitive impairment (CRCI), is colloquially referred to 
as “chemo brain” or “chemo fog” (Falleti, Sanfilippo, Maruff, Weih, & Phillips, 2005; Janelsins 
et al., 2011; Bender & Thelen, 2013; Pendergrass, Targum, & Harrison, 2018). It manifests in 
deficits of executive function, attention, learning and memory, and processing speed. These 
dysfunctions are associated with reduced quality of life and negatively impact daily functioning. 
Etiology remains unclear and is suggested to be a consequence of multi-faceted interactions of 
malignancy, treatment exposure, and biopsychosocial risk factors (e.g. age, stress, depression, 
fatigue) (Jean-Pierre, Johnson-Greene, & Burish, 2014). Currently, prevalence rates and 
symptomology reported vary across studies. An estimated 30% of patients pre-treatment, 75% 
during treatment, and 35% upon competition of treatment report cognitive impairment 
(Harrington, Hansen, Moskowitz, Todd, & Feuerstein, 2010; Wefel, Vardy, Ahles, & Schagen, 
2011). This discrepancy may be due to a variety of factors including heterogenous conceptual 
definitions of cognitive impairment, cross-sectional study design, lack of control groups and 
individual pre-treatment cognitive assessment, and variance in diagnostic cut-off points on 
cognitive measures which limits comparison across studies (Dietrich, Monjie, Wefel, & Meyers, 
2008; Wefel et al., 2011; Pendergrass, Targum, & Harrison, 2018). The goal was to study CRCI 
in patients with chronic lymphocytic leukemia, using a prospective longitudinal design utilizing 
self-report and objective cognitive assessments: Patient-Reported Outcomes Measurement 
Information System – Cognitive Function (PROMIS-CF), NIH Auditory Verbal Learning Test 
(AVLT), and the Controlled Oral Word Association Test (COWAT). 
Subjective and objective assessment of CRCI 
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Presently, CRCI lacks a standardized, gold standard, neuropsychological battery. 
Variance in CRCI literature is in part due to a failure for studies to specify domains of cognition, 
subjective or objective, being assessed. Subjective cognition consists of patient-reported or 
perceived cognitive abilities. Objective cognition infers performance on neuropsychological 
examinations as indicative of actual or true cognitive abilities. It is widely accepted that 
commonly used subjective and objective assessments do not converge and are postulated to 
capture different aspects of cognition (Braun, Rao, & Pirl, 2012; Jean-Pierre et al., 2014; Lycke 
et al., 2017; O’Farrell, Smith, & Collins, 2017). In a systematic review, researchers found, only 8 
out of 24 studies reported a significant relationship between subjective CRCI and objective 
CRCI across cancer groups (Hutchinson, Hosking, Kichenadasse, Mattiske, & Wilson, 2012).  In 
a meta-analysis of breast cancer patients, researchers found objective cognition was not 
associated with subjective cognition, fatigue, mood, or health-related quality of life (Cheung, 
Tan, & Chan, 2012). On the contrary, subjective CRCI has been associated with fatigue at pre-
treatment and across time along with mood (Lycke et al., 2017). It has been suggested that only 
objective verbal memory scores may be sensitive enough to be associated with subjective 
cognitive impairment and fatigue on the European Organization for Research and Treatment of 
Cancer – quality of life questionnaire (EORTC-QLQ) (Mehnert et al., 2007).  
Subjective CRCI or perceived cognitive impairment is assessed using self-report 
questionnaires and/or clinical interview. Subjective impairment has a high prevalence amongst 
patients and is associated with impairment in daily functioning such as employment and social 
functioning (Cheung et al., 2012). Self-reported cognitive difficulties have been identified as a 
significant stressor amongst patients and associated with poorer quality of life in both patients 
and survivors (Hutchinson et al., 2012; Jean-Pierre et al., 2014).  
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In contrast, objective CRCI is regarded as 1 to 2 standard deviations below the normative 
mean on neuropsychological tests assessing executive function. It is often reported as subtle 
impairment and permits normal range of cognitive abilities, yet, the prevalence rate of objective 
CRCI in solid tumor cancer patients ranges from 15% to 50% (O’Farrell et al., 2017). Impaired 
performance on objective measures can result more intensive neuropsychological assessments 
and allocation of resources to facilitate cognitive training and restoration in patients (Jean-Pierre 
et al., 2014; Von, Jansen, & Allen, 2014).  
Both cognitive domains are subjected to methodological confounds that should be taken 
under consideration when selecting and administering measures. It is possible that increased 
rates of subjective CRCI is a result of patient awareness of potential “chemo brain” or 
misattribution of pre-existing cognitive deficits to cancer or treatment (Lycke et al., 2017). 
Subjective measures often lack validated normative data to appropriately compare cancer 
patients (Janelsins et al., 2011; Hutchinson et al., 2012; Pendergrass et al., 2018). Objective 
CRCI assessments may be confounded by practice effects, differences between studies on the 
clinical cut-offs of impairment, and cognitive domains assessed may not be translatable to 
cognitive impairment patients experience in their day-to-day lives. Conducting objective 
assessments can be restricted by busy clinical settings and research protocol. Furthermore, 
evidence suggest objective assessments are not sensitive enough to detect mild cognitive deficits, 
resulting in the potential for underdiagnoses (Jean-Pierre et al., 2014). Current literature 
recommends usage of both subjective and objective assessments in current CRCI research to best 
capture domains of cognitive dysfunction in patients (Wefel et al., 2011; Joly et al., 2015).  
CRCI Past Research Findings 
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Currently, the CRCI literature is dominated by cross-sectional studies of breast cancer 
patients and survivors treated with adjuvant chemotherapy. Evidence suggest the prevalence of 
cognitive impairment in breast cancer patients may be determined by the reference or control 
group utilized (Scilder et al., 2010). When compared to study-specific healthy controls, 13.7 to 
45.5% of patients showed impairment versus 1 to 36.6% of patients when compared to published 
norms. Researchers found that cognitive impairment in breast cancer patients ranged from small 
to moderate, -0.03 to -0.51 standard deviation below controls (Falleti et al., 2015). A temporal 
impact of CRCI has been identified such that very mild cognitive impairment has been detected 
from one to nine years post treatment (Harrington et al., 2010). In one prospective study, when 
analyzed at a group level, cognitive decline was not detected amongst patients receiving adjuvant 
chemotherapy. However, at an individual level, 30.5% of patients demonstrated significant 
impairment post treatment (Wefel et al., 2004). Additionally, evidence supports a potential dose-
response or cumulative effect of chemotherapy on patients (Collins et al., 2013). Prospective 
results, controlling for pre-treatment performance, practice effects, and mood found that patients 
receiving high-dose chemotherapy showed more cognitive impairment compared to standard-
dose patients and controls.  
 CRCI has been studied in other cancer groups. Gynecological cancer survivors have 
been reported to have elevated subjective CRCI along with psychological measures of depression 
and anxiety (Zeng et al., 2017). Compared to healthy controls, survivors reported statistically 
higher subjective CRCI on the Functional Assessment of Cancer Therapy – Cognitive version 
(FACCT-Cog). Survivors who had received chemotherapy had higher rates of impairment 
(30.38%) than survivors of surgery (10.13%) along with greater anxiety and fatigue. Also, CRCI 
is observed amongst prostate cancer survivors who received androgen-deprivation therapy 
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(Gonzalez et al., 2015). The risk for cognitive impairment on objective measure was 70% higher 
in prostate cancer patients compared to controls. Impaired performance has been recorded up to 
12 months post treatment. Results from the primary literature of CRCI often lacks 
generalizability outside of adjuvant chemotherapy in breast cancer due to female gender, unique 
hormonal profiles, and disease-specific treatment (Hutchinson et al., 2012; Falleti et al., 2015). 
Regardless, evidence suggests that both subjective and objective CRCI is a prevalent adverse 
consequence in several cancer groups.  
CRCI and age 
Age is an established risk factor for normal, cognitive decline yet minimal literature 
specifically evaluates prevalence of cognitive decline in older cancer patients (Loh, 2016). In 
cancer patients over 70, cognitive impairment at pre-treatment was associated with decreased 
survival compared to survival for cognitively intact cancer patients (23 months vs 72 months 
respectively) regardless of exact age or disease prognosis (Robb, 2010). Cancer survivors over 
60 performed worse on the Digit Symbol Substitution Test and reported more issues with 
memory and confusion than age-matched healthy controls (Williams, Janelsins, Wijngaarden 
2016). However, the analysis from the Health and Retirement Study reported that cancer 
survivors did not have cognitive impairment compared to age-matched non-survivor controls 
(Porter, 2013). Studies may be limited due to low accrual and high attrition rates amongst older 
patients. Biological mechanisms of potential CRCI in older cancer patients are unknown and 
cognitive measures may not be validated for older individuals. Overall, the interaction of age, 
cancer history, and treatment may be associated with increased risk for cognitive impairment and 
poor quality of life in patients, suggesting age as an important covariate in future CRCI research. 
CRCI and hematological cancers 
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Limited research has assessed cancer-related cognitive impairment in hematological 
cancers. In them, however, cognition is an important predictor of patient mortality (Dubruille et 
al., 2015, Hshieh et al., 2018). Executive function deficits are more common than those of 
working memory however impairment on the 5-word delayed recall test has been associated with 
increased mortality in lymphoma and leukemia patients over 75 (Hshieh et al., 2018). In a 
retrospective study of lymphoma survivors, researchers determined widespread objective CRCI 
and subjective CRCI amongst survivors when compared to healthy controls (Krolak et al., 2017). 
Frequency of impairment was greater amongst survivors, particularly females (37% compared to 
5% for males).  Like prior CRCI literature, fatigue and anxiety were associated with subjective 
CRCI while reported pain was associated with objective CRCI. One study of acute myelogenous 
leukemia and myelodysplastic syndrome patients evaluated cognitive function, quality of life, 
and cytokine levels pre-treatment and after one month of chemotherapy (Meyers, Albitar, & 
Estey, 2005). Results showed, cognitive impairment and significant fatigue pre-treatment were 
not correlated, but were with correlated increased cytokine levels. Twenty-five percent of 
patients had difficulties with executive function, suggesting that increased immune activation 
negatively impacts cognition. Chronic myeloid leukemia patients receiving allogeneic 
hematopoietic stem cell transplantation saw an increase in impairment on at least one 
neuropsychological assessment from baseline to 18 months. (Williams et al., 2016). In summary, 
the few studies conducted with hematologic patients have reported CRCI amongst them 
compared to controls. Further research into other prevalent non-solid tumor cancers is warranted.  
Chronic lymphocytic leukemia (CLL) 
 
Chronic lymphocytic leukemia (CLL) is the most common adult leukemia in the Western 
hemisphere (Nabhan & Rosen, 2014). Regarded as an illness of immune dysfunction; pathology 
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presents an accumulation of abnormal, malignant lymphocytes (Rai et al., 1975; Byrd, 
Stilgenbauer, & Flinn, 2004). Standard diagnostic techniques involve a blood test, bone marrow 
biopsy, and measurement of lymph nodes. Risk factors include age (approximately 66% of 
diagnoses are in individuals over 60), sex, ethnicity, and genetic polymorphisms. Symptomology 
commonly reports fatigue, weakness, and enlarged lymph nodes. There is variance in disease 
progression and symptomology, such that some patients show similar survival rates to age-
matched healthy controls. CLL treatment is non-curative; treatment aims to slow the rate of 
abnormal lymphocytosis amongst intermediate or advance staged patients. Temporary remission 
is often followed by relapse and additional treatment (Nabhan, Raca, & Wang, 2015). Patients 
who become refractory to frontline treatment typically have a worse prognosis, limited treatment 
options, and are at risk for increased mortality compared to responsive patients (Fischer et al., 
2011). Additional treatment regimens are offered after consideration of patient’s expected 
survival, age, and the potential short and long-term toxicities associated with later treatments 
(Byrd et al., 2004). Though much of CRCI research focuses on the detriments of chemotherapy, 
little research has examined the possible cognitive effects of immunotherapies. 
CRCI in CLL 
Only four studies have examined subjective cognition only using the EORTC QLQ-30 
cognitive functioning subscale (Williams et al., 2016). Patients, in treatment and in remission, 
scored significantly lower than published normative means and healthy controls across studies 
(Holzner et al., 2004; Else et al., 2008; Pamuk et al., 2008). Previously treated chemotherapy 
CLL patients performed better than previously untreated patients (77.1 vs. 72.5, p>0.05) 
(Holzner et al.,2004).  A cross-sectional study in the Netherlands reported patients actively 
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receiving treatment for CLL were significantly more impaired than non-treated patients (Holtzer 
et al., 2015). 
Current study 
No study has assessed objective cognition or cognitive change through treatment in CLL 
patients. CLL patients commonly report cancer-specific fatigue, and symptoms of depression and 
anxiety (Morrison et al., 2016). Older CLL patients have greater risk for negative 
chemotherapeutic side effects than younger CLL patients (Roswell-Turner & Barr, 2017). These 
factors have been associated with increased risk of cancer-related cognitive impairment (Dietrich 
et al., 2008; Hutchinson et al., 2012; Joly et al., 2015).  
The current study evaluates subjective and objective cognition from pre-treatment to 12 
months in CLL patients receiving a novel combination of immunotherapeutic agents 
(Obinutuzumab, Venetoclax, and Ibrutinib). Differences between patients with no prior treatment 
history (Treatment Naïve, TN) and at least one prior treatment (Relapse/Refractory, R/R) are 
assessed. Covariates of interest (e.g. age, and symptoms of depression and anxiety) that have 
been associated with increased risk of CRCI are assessed in exploratory analyses.  Longitudinal 
study design, cognitive measures, and statistical analyses are in accordance with the International 
Cancer and Cognition Task Force recommendations for cancer-related cognitive impairment 
research (Wefel et al., 2011). This study hypothesizes: 
1) At pre-treatment, R/R patients will have more cognitive impairment such that R/R 
will have lower objective scores and higher rates of subjective complaints than TN 
patients. 
2) Across time, both R/R and TN patients will experience more cognitive impairment 
across all measures. 
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3) R/R patients will have more cognitive impairment with time compared to TN 
patients. 
Exploratory analyses will assess covariates such as age, and symptoms of depression and anxiety 
for potential moderating effects between treatment cohorts across measures and time. 
Method 
Study Design 
 
 A phase II clinical trial assessing the efficacy of the novel combination of 
immunotherapeutic agents (Obinutuzumab, Venetoclax, Ibrutinib) for CLL patients at The James 
Comprehensive Cancer Center at The Ohio State University (OSU) was utilized. Inclusion 
criteria included individuals ≥ 18 years of age, without treatment within the past month, and 
without secondary, significant life-threatening diseases. Prior to enrollment in trial and data 
collection, informed consent was obtained.  
Participants  
 
Forty-four (44) patients with CLL were accrued. Patients were primarily Caucasian (one 
patient was African American) and 61% were male (n = 27). The average age was 59 (SD = 11) 
with an average of 15 years of education (SD = 2.7).  Patients were in one of two groups. Cohort 
1 (n = 23, Treatment Naïve, TN) participants had no prior treatment for their diagnosis of CLL. 
Cohort 2 (Relapse/Refractory, R/R) participants received at least one prior treatment and either 
relapsed from a period of remission or failed to respond to initial treatment. There was a 
significant difference of age between TN patients (M = 59.22; SD=13.83; range = 25-87) and 
R/R patients (M =59.24; SD =7.20; range = 43-71; t(42) = -0.06, p =.01).  
Measures 
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Subjective cognitive. Patient-Reported Outcomes Measurement Information System – 
Cognitive Function short form (PROMIS-CF) is a self-report questionnaire designed to measure 
patient-reported complaints with cognition (PROMIS: List of adult measures, 2017). The 
PROMIS-CF version 2.0 short form subscale consists of eight questions regarding cognitive 
functioning and distress in daily life. Questions are using a 5-point Likert scale (0=Never to 
4=Very Often) in the context of “In the past 7 days”. Items are summed to create a total score 
and scores range from 0 to 32. The higher the score, the higher perceived cognitive impairment 
in participants. The PROMIS-CF does not have published normative date for clinical cut offs 
therefore impairment is assessed as positive endorsement on any question. 
Objective cognitive. NIH Toolbox Auditory Verbal Learning Test (AVLT) assesses 
immediate recall (Kallen et al., 2012). Administrators present a list of 15 random words and 
participants are prompted to recall as many words as possible. This test was completed three 
times and participant’s score is the sum of words recalled. Higher scores are associated with 
better memory and recall abilities. Z-scores were calculated using age and gender norms 
accessed from the NIH Toolbox technical manual. (Slotkin et al., 2012). The Controlled Oral 
Word Assessment Test (COWAT) assesses phonemic verbal fluency, spontaneous word 
generation (Benton, 1994). Administrators prompted participants with a letter (i.e. “F”, “A”, “S”) 
and provided one minute for participants to generate as many words that began with each 
corresponding letter. Scores consisted of total of words generated. Higher scores are associated 
with selective attention, executive control, and the ability of internal response generation. Z-
scores were calculated based off age and education norms from 1,300 healthy controls 
(Tombaugh, Kozak, & Rees, 1999).  
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Affect. The Patient Health Questionnaire – 9 (PHQ-9) assesses symptoms of depression 
using a 4-point Likert scale (0 = Not At All to 3 = Nearly Every Day) (Kroenke et al., 2002). 
Items are totaled and scores range from 0 to 27. Higher scores are associated with increased 
symptoms of depression. The Generalized Anxiety Disorder – 7 (GAD-7) assesses symptoms of 
anxiety using a 4-point Likert scale (0 = Not At All to 3 = Nearly Every Day) (Spitzer et al., 
2006). Items are totaled and scores range from 0 to 21. Higher scores are associated with 
increased symptoms of anxiety.  
Procedure 
Patients were accrued and assessed in a medical oncology clinic, The James 
Comprehensive Cancer Center at The Ohio State University. Assessments were conducted at 
pre-treatment, 6 months, and 12 months. This included administration of immunotherapies 
(Obinutuzumab, Ibrutinib, and Venetoclax) at 6 months and 12 months along with psychometric 
measures at pre-treatment, 6 months, and 12 months. Psychometric measures were administered 
by trained researchers, graduate students, and undergraduate research assistants. PROMIS-CF, 
AVLT, COWAT scores were assessed at pre-treatment, 6 months, and 12 months of treatment. 
PHQ-9 and GAD-7 scores were assessed at pre-treatment and 12 months of treatment.  
Analytic Plan 
Statistical analyses were conducted using SPSS 24.0 (IBM, 2016). Descriptive statistics 
for demographic and clinical characteristics were calculated and independent samples t-tests 
were used to assess differences between cohorts. Criteria for objective cognitive impairment 
included a z-score ≤ -1.5 SD on both assessments or a z-score ≤ -2 SD on one assessment. To 
account for missing data and confounding variables, a linear mixed model was used, a 
recommended method for repeated measure analyses (Pinheiro & Bates, 2000). Linear mixed 
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model was first conducted to test for the effects of cohort (TN, R/R), time (pre-treatment, 6 
months, 12 months) and the interaction of cohort and time. Separate higher order models were 
conducted controlling for covariates of interest (age followed by PHQ-9 and GAD-7 scores) to 
test for moderating effects of cohort, time, and interaction of cohort and time. 
Results 
All participants were included in final analyses despite patient attrition (Figure 1). 
Independent-samples t-tests showed there were no significant differences between cohorts across 
gender, years of education, relationship status (Table 1). There were no significant differences 
between cohorts on all cognitive measure and PHQ-9 or GAD-7 scores at pre-treatment (Table 
2). Across cohorts, subjective CRCI was reported in 33 out of 44 (75%) patients at pre-treatment 
(M = 7.48, SD = 7.91, range = 1-31). At 6 months, 28 out of 40 (60%) patients (M = 6.45, SD = 
7.13, range of scores = 1-28) and at 12 months, 18 out of 28 patients (64.3%) (M = 7.29, SD = 
8.34, range =1-29) reported some form of cognitive difficulties on the PROMIS-CF. Objective 
CRCI was less frequently observed. At pre-treatment, 4 out of 44 patients (9%) showed cognitive 
impairment on either or both objective measures. At 6 months, 3 out of 40 patients (7.5%) and at 
12 months, 1 patient out of 28 (3.6%) showed impairment on either or both objective measures.  
Subjective cognition 
Figure 2 provides a plot of mean PROMIS-CF scores of cohorts across time. Linear-
mixed model analyses of PROMIS-CF scores yielded null effects of cohort, time and the 
interaction of cohort and time on subjective cognition such that PROMIS-CF scores remained 
constant across cohorts and across treatment. Additional, higher order models containing 
covariates, PHQ-9 and GAD-7, yielded a statistically significant moderating effect of PHQ-9 
score, F (1,67) = 51.51, p = .00, and GAD-7 score, F (1, 52) = 17.21, p = .00 on subjective 
COGNITIVE IMPAIRMENT IN CLL                                                                                                        16 
 
cognition for both cohorts from pre-treatment to 12 months. The model controlling for age 
yielded null effects on subjective cognition.  
Objective cognition 
 Figure 3 provides a plot of mean AVLT scores of cohorts across time. Linear-mixed 
model analyses of AVLT scores yielded significant effects of cohort, F (1, 43) = 3.76, p = .05 
and of time, F (1,69) = 3.07, p =.05, while the interaction of cohort and time was null. R/R 
patients’ scores improved while TN patients’ scores remained stable across treatment. In 
additional models containing covariates, there was no main effect of PHQ-9, GAD-7, or age on 
AVLT scores. 
Figure 4 provides a plot of mean COWAT scores of cohorts across time. Linear-mixed 
model analyses of COWAT scores yielded a significant effect of time, F (2, 66) = 10.75, p = .00, 
such that both cohorts’ scores improved across treatment. Main effect of cohort and interaction 
of cohort and time were null. In additional models containing covariates, there was no main 
effect of PHQ-9, GAD-7, or age on COWAT scores.  
Discussion 
While limited research has assessed subjective and objective CRCI in CLL patients, rates 
were found to be comparable to those in other cancer groups (Harrington et al., 2010, Wefel et 
al., 2011, O’Farrell, Smith, & Collins, 2017). Subjective CRCI was reported amongst patients 
more frequently (75-60%) than objective CRCI (9-3.6%) as reported in prior literature 
(Hutchinson et al., 2012, Joly et al., 2015).  
Results did not support hypothesized adverse effects of prior treatment history on 
objective performance or rates of cognitive complaints at pre-treatment. Objective CRCI was 
only found in five patients across time with TN patients displaying a higher frequency of scoring 
COGNITIVE IMPAIRMENT IN CLL                                                                                                        17 
 
in the impaired direction. Treatment cohorts showed similar rates of subjective complaints at pre-
treatment. These findings neither support higher rates of subjective CRCI reported in treatment 
receiving CLL patients compared to non-treated patients (Holtzer et al.,2015) or lower rates of 
subjective CRCI in previously treated patients compared to untreated patients (Holzer et al., 
2004). Results suggest that R/R patients are not at increased risk for objective or subjective 
CRCI at pre-treatment assessment. Objective cognition in TN patients should be assessed in 
further studies to determine potential adverse effects of initial treatment for CLL. 
Results did not support hypothesized increase in cognitive impairment across treatment. 
Both treatment cohorts either improved or remained stable on cognitive measures.  TN and R/R 
patients showed similar improvement on COWAT scores across time. R/R patients improved on 
AVLT scores while TN patients remained stable from pre-treatment to 12 months. Both cohorts 
averaged stable rates of cognitive complaints across treatment. Results do not support increased 
objective CRCI with time as reported in chronic myeloid leukemia patients (Williams et al., 
2016). Cognition has not been assessed in CLL patients receiving immunotherapy. These 
findings suggest this treatment may not associated with increased cognitive impairment across 
time. Further research assessing both subjective and objective cognition across time amongst 
CLL patients is needed to validate these findings.  
Finally, results did not support a hypothesized interaction of cohort and time such that 
R/R patients would show more cognitive impairment across treatment compared to TN patients. 
Treatment history and time impacted objective cognition on AVLT scores such that R/R patients 
had improved verbal recall abilities across treatment compared to TN patients that remained 
relatively stable. Across time, COWAT scores improved regardless of treatment history. 
Subjective cognition was not impacted by treatment history or time. These results do not support 
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the previous CRCI literature which shows increased cognitive impairment across treatment and 
with increased treatment dosage (Collins et al., 2013). Results suggest that treatment history does 
not have an adverse effect across treatment such that R/R patients are not at increased risk of 
subjective or objective CRCI compared to TN patients throughout treatment. Further research is 
necessary to assess the impact of treatment history in this cancer group. 
Constant subjective rates of cognitive complaints across treatment cohorts were not 
reflected with similar stability of objective performance. Objective cognitive improvement on 
COWAT scores were recorded in both cohorts. While improvement on AVLT scores were 
observed amongst R/R patients. These results support prior literature stating subjective and 
objective cognitive measures do not converge and are assessing different domains of cognition as 
observed in other cancer groups (Braun et al., 2012; Jean-Pierre et al., 2014; Lycke et al., 2017; 
O’Farrell et al., 2017).  
Furthermore, exploratory analyses of covariates of interest, symptoms of depression and 
anxiety, supported prior literature that subjective cognition is impacted by self-reported 
symptoms of depression and anxiety whereas objective cognition is not (Cheung et al., 2012; 
Lycke et al., 2017). Across cohorts, patients self-reported symptoms of depression and anxiety 
moderated rates of cognitive complaints. This study does not support literature suggesting that 
increased age increases risk for cognitive impairment (Williams et al., 2016). These findings 
suggest that CLL patients are not increased risk of cognitive impairment despite commonly 
presenting risk-factors. 
 The current study is the first to assess objective cognition amongst CLL patients. 
Additionally, subjective and objective cognition were studied longitudinally with the added 
comparison of prior treatment history. This study’s design, measures, and statistical analyses are 
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all in accordance with the International Cognition and Cancer Task Force’s recommendations for 
CRCI research (Wefel et al., 2011).  
Limitations of this study include a small patient population which may have hindered the 
ability to detect statistically significant differences across measures. Potential confounds include 
risk for practice effect on objective cognitive measures such that improvement on measures may 
not have been indicative of true cognitive abilities. However, it has been suggested that waiting 6 
to 12 months between repeated objective assessment minimizes the potential of practice effects 
(Jean-Pierre et al., 2014). While pre-treatment assessments were administered prior to 
immunotherapeutic treatment some patients received anti-histamines prior to or during in-person 
assessment potentially impacting cognitive abilities. Furthermore, the covariates such as fatigue 
and general affect were not studied.  
Future research might utilize a complete neuropsychological battery along with 
subjective measures to assess a wider range of cognitive domains and potential impairment. 
Continued usage of recommended cognitive measures (e.g. PROMIS-CF, AVLT, and COWAT) 
across cancer groups along with repeated measure analyses is essential to continue throughout 
future CRCI studies. Increased assessment of cognition in specific cancer populations other than 
breast cancer patients is necessary to fully comprehend CRCI.  
 In conclusion, in CLL patients, treatment history did not negatively impact subjective or 
objective cognitive abilities at pre-treatment or across treatment. CLL patients are not at 
increased risk for CRCI despite the prevalence of risk factors associated with increased cognitive 
impairment. Further research is warranted to validate the findings of this novel study of 
cognition amongst the CLL population. 
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Table 1 
 
 
 
 
 
 
 
 
 
        
 
 
 
 
 
 
 
 
 
 
 
 
Baseline Patient Demographics Between Treatment Cohorts
Category M (SD) N (%) M (SD)      N (%)      p
Age (in years) 59.2 (13.83) 59.2 (7.20) 0.01
Gender (Male) 14 (61%) 13 (62%) 0.89
Married/Partnered (Yes) 19 (83%) 18 (86%) 0.58
Education (in years) 15.0 (2.61) 15.4 (2.75) 0.89
Cohort
R/R (n = 21)TN (n = 23)
Note. TN = treatment naïve (no prior treatment); R/R = relapse/refractory ( ≥ 1 prior treatment).
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Table 2 
 
 
 
 
Descriptive Statistics of Clinical Characteristics of Treatment Cohorts
       M        SD
Cognition
PROMIS-CF
pre-treatment 7.61 6.65 7.33 9.27 7.48 7.91
6 months 6.04 5.79 7.00 8.79 6.45 7.13
12 months 7.71 8.05 6.64 9.11 7.29 8.34
Total 7.06 6.70 7.06 8.88 7.06 7.70
AVLT 
pre-treatment 0.30 0.76 0.46 0.76 0.38 0.76
6 months 0.37 0.92 1.12 0.95 0.69 1.00
12 months 0.49 0.86 0.76 0.93 0.59 0.88
Total 0.38 0.84 0.76 0.90 0.54 0.88
COWAT 
pre-treatment -0.30 1.25 -0.43 1.05 -0.36 1.15
6 months 0.08 1.35 0.15 1.15 0.11 1.25
12 months 0.20 1.29 0.18 0.63 0.19 1.06
Total -0.03 1.29 -0.09 1.03 -0.05 1.18
Affect
PHQ-9 
pre-treatment 4.17 3.05 3.95 5.03 4.07 4.07
12 months 3.12 4.00 2.64 3.58 2.93 3.78
Total 3.73 3.48 3.50 4.57 3.63 3.97
GAD-7 
pre-treatment 3.26 2.80 3.62 4.17 3.43 3.48
12 months 2.35 2.78 2.00 2.53 2.21 2.64
Total 2.88 2.79 3.43 3.48 2.96 3.22
Note. TN = treatment naïve (no prior treatment); R/R = relapse/refractory ( ≥ 1 prior treatment); 
an = 23 (pre-treatment), 23 (6 months), 17 (12 months); bn = 21 (pre-treatment), 17 (6 months), 
11 (12 months);  cn = 44 (pre-treatment), 40 (6 months), 28 (12 months);
PROMIS = patient-reported outcomes measurement information systems - cognitive function; 
AVLT = auditory verbal learning test; COWAT = controlled oral word association test; 
PHQ-9 = patient health questionnaire - 9; GAD-7 = generalized anxiety disorder - 7
Measure                             M            SD            M             SD       M  SD 
Cohort
TNa R/Rb Totalc
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Figure 1. Flow of Participants from pre-treatment through 12 months  
Enrolled (n = 44) 
No prior treatment, 
Treatment Naïve (TN)   
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Figure 2. PROMIS-CF score (mean) by treatment cohort showing null effects of cohort, time, 
and interaction of cohort and time. 
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Figure 3. AVLT score (means) of treatment cohorts showing a significant effect of cohort, F 
(1,43) = 3.76, p = .05, and of time, F (1,69) = 3.07, p = .05 such that Relapse/Refractory patients 
AVLT scores improved across time compared to Treatment Naïve patients. No significant 
interaction of cohort and time.  
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 Figure 4. COWAT score (means) of treatment cohorts across showing a significant effect of 
time, F (2,66) = 10.75, p = .00 such that COWAT scores improved across time in both treatment 
cohorts. Main effect of cohort and interaction of cohort and time were null. 
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